Novo A/S published an annual report Wednesday which could, at first glance, give some cause for concern. But the company’s CEO, Kasim Kutay, is optimistic. Viewed in a broader scope, business is still booming, he says.
“You have to remember that investment is a long-term business, and if you look at the return on investment over the past five or 10 years, it’s still significant. Novo is a leading company that most players want to work with,” the CEO says in an interview with MedWatch.